General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Research Analysts’ Upgrades for September 24th (AWH, BANC, BNTX, CMA, COLB, CRM, ESI, LOW, MESO, NFLX) | news.google.com • |
Learn to Evaluate (MESO) using the Charts | news.google.com • |
Mesoblast (NASDAQ:MESO) Upgraded by Maxim Group to Buy | news.google.com • |
Mesoblast upgraded to Buy at Maxim on Ryoncil opportunity | news.google.com • |
Mesoblast (NASDAQ:MESO) Trading Up 6.4% | news.google.com • |
Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-04 | 2024-06 | 0 | N/A | N/A | N/A |
2024-07-04 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-01 | 2023-12 | 0 | N/A | N/A | N/A |
2024-01-02 | 2023-09 | 0 | -0.28 | N/A | N/A |
2023-08-30 | 2023-06 | -0.32 | -0.28 | 0.04 | 12.50% |
2023-08-30 | 2023-06 | -0.32 | -0.26 | 0.06 | 18.75% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-20 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-30 | Jefferies | Upgrade | Hold | Buy |
2023-08-30 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Maxim Group | Downgrade | Buy | Hold |
2023-08-03 | William Blair | Downgrade | Outperform | Market Perform |
2023-08-03 | Piper Sandler | Downgrade | Overweight | Neutral |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Penbrook Management LLC | 285.35K | 350.98K | 0.18% |
2023-06-29 | Group One Trading, L.P. | 250.35K | 978.87K | 0.15% |
2023-06-29 | Morgan Stanley | 214.68K | 839.41K | 0.13% |
2022-09-29 | Ronit Capital LLP | 150.00K | 381.75K | 0.09% |
2023-06-29 | Blackrock Inc. | 140.72K | 550.20K | 0.09% |
2023-06-29 | Jane Street Group, LLC | 109.27K | 427.25K | 0.07% |
Split | Date |
---|---|
1 : 2 | 2024-01-10 |
1 : 2 | 2024-01-08 |
1 : 2 | 2024-01-05 |
Here we go ~ 5ma upup
Trading halt? I think with the recent discovery of medicine to cure lower back pain, we may be looking at a buy out, halted given the short float, I’m thinking 3x the price. $MESO i really don’t just it’s just a thought, I’m hoping for the best
Can this go to a valuation of $5billion? Curing lower back pain, now children from COVID risks, and others in the pipeline. $50 sounds reasonable I think for $MESO and $CRDF curing it prostate cancer I think that can go to 1-2billion so $20-30 seems reasonable. $ADXN shooting for 10x with a 1b valuation from their results.
Bought 501.